{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:24Z","timestamp":1793018124943,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01921-9","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:27:59Z","timestamp":1790926079000},"page":"5839-5853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Deignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"8","key":"1921_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s13555-025-01456-5","volume":"15","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Feldman SR, Fitzgerald T, et al. Patient-reported outcomes by baseline body surface area involvement among individuals initiating biologic therapy: results from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2025;15(8):2117\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1921_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jdv.18689","volume":"37","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37(2):348\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1921_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","volume":"8","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gondo GC, Bell S, et al. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthritis. 2023;8(3):100\u20136.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1921_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1921_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-023-01065-0","volume":"14","author":"ME Horner","year":"2024","unstructured":"Horner ME, Orroth KK, Ma J, Duan Y, Cordey M. Redefining disease severity with special area involvement and reflecting on treatment patterns in a real-world psoriasis population. Dermatol Ther (Heidelb). 2024;14(1):187\u201399.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1921_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90(3):485\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1921_CR7","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s13555-022-00747-5","volume":"12","author":"Y Okubo","year":"2022","unstructured":"Okubo Y, Takahashi H, Hino R, et al. Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label, single-arm study. Dermatol Ther (Heidelb). 2022;12(6):1469\u201380.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1921_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86(1):77\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1921_CR9","first-page":"801","volume":"16","author":"B Strober","year":"2017","unstructured":"Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1921_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","volume":"83","author":"AS Van Voorhees","year":"2020","unstructured":"Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83(1):96\u2013103.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1921_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1921_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61\u201378.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1921_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023;13(6):1329\u201346.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01921-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:05:56Z","timestamp":1793016356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01921-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01921-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bruce Strober has been a consultant, investigator, scientific co-director, speaker, and\/or holder of stock options for AbbVie, Almirall, Alumis, Amgen Inc., Apogee Therapeutics, Arcutis Biotherapeutics, Bristol Myers Squibb, CorEvitas Psoriasis and Generalized Pustular Psoriasis Registries, Dimagi, Eli Lilly, Immunovant, Incyte, Johnson & Johnson, LEO Pharma, Meiji Seika Pharma, Mindera Health, Neurocrine Biosciences, Novartis, Oruka Therapeutics, Pfizer, Protagonist Therapeutics, Regeneron Pharmaceuticals, Sanofi, selectION, Takeda, and UCB. Mark Lebwohl has been an investigator and\/or consultant for AbbVie, Almirall, AltruBio, Amgen Inc., AnaptysBio, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, CorEvitas Psoriasis Registry, Dermavant Sciences, Eli Lilly, EPI Health, Evommune, Forte Biosciences, Galderma, Genentech, Incyte, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera Health, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Seanergy, Strata Oncology, Trevi Therapeutics, UCB, and Verrica Pharmaceuticals. Peter van de Kerkhof has been a consultant and\/or speaker for Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB. Linda Stein Gold has received honoraria, grants, and\/or research funding as a speaker, investigator, or advisory board member from AbbVie, Amgen Inc., Arcutis Biotherapeutics, Celgene Corporation, Dermavant Sciences, Dermira, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, UCB, and Valeant Pharmaceuticals. Joseph F. Merola has been a consultant and\/or investigator for AbbVie, Amgen Inc., AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and UCB. Yukari Okubo has received research grants from Eisai, Maruho, Shiseido, and Torii Pharmaceutical; received honoraria from AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, JIMRO, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB; and participated in clinical trials for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Maruho, Pfizer, Sun Pharma, and UCB. Paolo Gisondi has been a consultant for and received grant\/research support from AbbVie, Amgen Inc., Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Zhenwei Zhou, Siddharth Chaudhari, and Cynthia Deignan are employees and stockholders of Amgen Inc. Ulrich Mrowietz has been an adviser for, received speakers\u2019 honoraria from, received grants from, and\/or participated in clinical trials for AbbVie, Aditxt, Almirall, Amgen Inc., Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Dr. Reddy\u2019s Laboratories, Eli Lilly, Foamix Pharmaceuticals, Formycon, Immunic Therapeutics, Janssen, LEO Pharma, medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre Group, Sanofi, UCB, and UNION Therapeutics. Mark Lebwohl, Peter van de Kerkhof, and Paolo Gisondi are Editorial Board members of\n                      Dermatology and Therapy\n                      . Mark Lebwohl, Peter van de Kerkhof, and Paolo Gisondi were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All six trials were approved by the institutional review board\/ethics committee before commencement and were conducted in compliance with Good Clinical Practice, the International Council for Harmonisation Guideline E6, the Declaration of Helsinki, and applicable regulatory requirements. Patients provided written informed consent before any trial-related procedures. A list of the institutional review boards\/ethics committees for the included studies is provided in Table\n                      \n                      .","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}